PARIS (Reuters) -France's finance minister criticised on Thursday a decision by French drugmaker Sanofi to invest at least $20 billion in the United States through to 2030, as France aims to get more companies investing in the country rather than abroad. "It's clear it was not something that was nice to see and it was an unpleasant announcement," finance minister Eric Lombard told BFM Business TV. "It sends out a bad signal," he also said, adding he hoped Sanofi would continue to invest in France. The French drugmaker, one of the world's largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday that it planned to expand its U.S. manufacturing capacity through direct investments in Sanofi sites, and partnerships with other domestic manufacturers. Sanofi's decision was the latest one from leading drugmakers which have been expanding their U.S. presence in response to President Donald Trump's trade policies. (Reporting by Sudip Kar-Gupta;Editing by Benoit Van Overstraeten) View Comments
French finance minister criticises Sanofi's $20 billion USA investment decision
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...